induct
robust
neutral
antibodi
nab
respons
like
essenti
specif
cellmedi
immun
cmi
multipl
antigen
develop
effect
prevent
therapeut
vaccin
hepat
c
viru
hcv
infect
human
date
data
immunogen
replicationdefect
vaccinia
viru
deriv
tiantan
strain
rntv
base
hcv
vaccin
primat
report
studi
describ
detail
immunogen
variou
vaccin
candid
rhesu
macaqu
includ
rntvbase
replicationdefect
recombin
adenovir
rad
base
hcv
vaccin
well
hcv
pseudotyp
viruslik
particl
hcvpp
data
show
radhcv
vaccin
boost
induc
robust
cmi
prime
boost
hcvpp
enhanc
antigenspecif
nab
respons
radhcv
vaccin
howev
cmi
enhanc
vaccin
includ
rntvhcv
prime
induc
robust
antigenspecif
antibodi
particularli
nab
cmi
respons
furthermor
robust
longerlast
cmi
higher
cytokin
level
type
especi
result
boost
radhcv
conclud
rntvbase
hcv
vaccin
induc
robust
nab
cmi
combin
heterogen
primerboost
strategi
show
promis
develop
human
hcv
vaccin
approxim
million
peopl
worldwid
chronic
infect
hepat
c
viru
hcv
put
higher
risk
liver
cirrhosi
liver
cancer
associ
death
peopl
annual
although
medic
improv
rapidli
develop
effect
vaccin
hcv
especi
therapeut
one
remain
top
prioriti
fortun
hcvinfect
individu
spontan
clear
viru
acut
stage
infect
research
identifi
sever
factor
associ
viral
clearanc
could
facilit
develop
effect
hcv
vaccin
variou
studi
found
induct
mainten
strong
helper
cytotox
tcell
immun
respons
play
pivot
role
viral
clearanc
defenc
chronic
hcv
infect
effect
vaccin
induc
multipl
viral
antigenspecif
tcell
respons
especi
immun
respons
time
neutral
antibodi
nab
induc
candid
vaccin
recogn
bind
varieti
genotyp
hcv
multipl
site
prevent
infect
also
immun
respons
induc
immunogen
regul
cytokin
eg
determin
outcom
hcv
infect
integr
cytokin
test
although
cytokin
product
majorli
primarili
genet
makeup
individu
may
assist
assess
efficaci
candid
vaccin
antigenpres
pathway
mediat
modul
viral
vector
regul
effici
antigenpresent
host
immun
respons
much
research
sever
hcv
vaccin
candid
includ
peptid
protein
dna
viruslik
particl
viral
vectorbas
vaccin
develop
immunogen
potenti
vaccin
combin
describ
laboratori
anim
human
previou
studi
reveal
recombin
viru
vector
rad
recombin
vaccinia
viru
rvv
advantag
term
induct
cellular
immun
respons
moreov
pseudotyp
viruslik
particl
hcv
envelop
protein
hcvpp
deriv
recombin
retrovir
lentivir
vector
induc
hightitr
antigenspecif
antibodi
nab
heterolog
primeboost
immun
seem
good
strategi
enhanc
humor
cellular
immun
respons
radbas
vaccin
use
prime
vaccin
follow
boost
hcvpp
combin
radand
dnaor
mvabas
vaccin
prove
efficaci
stimul
cellmedi
immun
cmi
howev
heterolog
promeboost
regimen
prime
hcvpp
boost
rad
rvv
may
also
potenti
rvv
deriv
tiantan
strain
rvvt
wide
use
smallpox
vaccin
china
prove
less
virul
pathogen
wr
strain
furthermor
delet
gene
associ
host
rang
virul
c
k
digest
fragment
hind
iii
develop
recombin
replicationdefect
vaccinia
tiantan
strain
viral
vector
rntv
well
propag
primari
chick
embryo
fibroblast
lack
replic
abil
primat
rabbit
therefor
much
safer
rvvt
date
data
immunogen
rntvbase
hcv
vaccin
primat
report
hcv
structur
protein
might
induc
nab
activ
tcell
respons
mediat
viral
clearanc
essenti
hcv
clearanc
induc
earli
sustain
cellmedi
immun
respons
therefor
structur
protein
antigen
target
hcv
vaccin
develop
due
safeti
consider
integrationdefici
lentivir
vector
use
captur
hcv
envelop
protein
insert
rel
well
conserv
nonstructur
protein
transfer
genom
target
antigen
recent
studi
demonstr
effect
recombin
viral
vectorbas
vaccin
primeboost
strategi
sever
clinic
trial
research
begun
focu
increasingli
replicatingdefici
vaccinia
viru
ankara
mva
base
vaccin
although
natur
host
macaqu
proven
import
vaccin
model
predict
success
human
immun
respons
multipl
antigen
similar
macaqu
immun
system
human
compar
number
vaccin
regim
macaqu
use
variou
hcv
vaccin
candid
ie
radhcv
rntvhcv
hcvpp
report
knowledg
first
describ
optim
rntvbase
hcv
vaccin
regim
elicit
robust
cmi
crossnab
respons
macaqu
combin
radhcv
vaccin
candid
construct
enrich
radhcv
rntvhcv
hcvpp
vaccin
candid
figur
report
previou
work
express
infect
confirm
eleven
monkey
divid
three
group
tabl
receiv
im
immun
radhcv
rntvhcv
hcvpp
tabl
blood
sampl
assess
hcvantigenspecif
cellmedi
immun
cmi
elispot
luminex
fill
triangl
indic
time
point
luminex
detect
multipl
cytokin
week
antibodi
igg
neutral
antibodi
nab
titr
assess
everi
week
immun
invert
triangl
nab
analysi
week
four
monkey
immun
radhcv
assess
week
indic
italic
number
tabl
group
evalu
term
immunogen
figur
first
assess
hcvspecif
antibodi
respons
follow
administr
variou
vaccin
regimen
figur
robust
antibodi
induc
among
monkey
group
c
prime
hcvpp
rntvhcv
figur
signific
enhanc
antibodi
hcv
target
antigen
observ
boost
hcvpp
radhcv
figur
singl
inject
rntv
produc
significantli
higher
antibodi
titr
singl
inject
hcvpp
radhcv
p
rntvhcv
prime
group
titr
decreas
slowli
next
month
hcv
p
p
antibodi
also
detect
heterolog
boost
radhcv
figur
titr
antibodi
low
group
prime
singl
radhcv
antibodi
titr
enhanc
second
radhcv
inject
p
boost
hcvpp
increas
antibodi
titr
persist
week
group
c
figur
howev
increas
product
antibodi
detect
boost
rntvhcv
group
c
figur
differ
among
three
group
compar
time
point
signific
differ
level
antibodi
among
three
group
prime
hcvpp
rntvhcv
radhcv
although
antibodi
titr
higher
group
prime
rntvhcv
figur
addit
respons
group
b
rntvhcv
prime
radhcv
boost
significantli
higher
two
group
p
week
figur
twelv
rhesu
macaqu
divid
three
group
immun
radhcv
rntvhcv
hcvpp
describ
tabl
result
express
g
j
igg
b
e
h
k
igg
c
f
l
igg
titr
determin
use
serial
twofold
dilut
sera
sera
neg
preimmun
test
dilut
plot
detect
limit
first
three
row
ai
indic
titr
chang
individu
median
respons
standard
error
repres
bar
group
shown
end
line
jl
experi
ai
mean
triplic
determin
sampl
shown
asterisk
denot
signific
differ
comparison
control
respons
time
point
associ
p
valu
provid
text
p
p
wilcoxon
signedrank
test
crossnab
hcv
also
induc
prime
rntvhcv
hcvpp
next
assess
crossneutr
abil
hcvpp
pseudotyp
protein
five
genotyp
hebei
pseudoparticl
envelop
protein
g
vsv
vsvgpp
use
control
serum
sampl
taken
week
week
prime
hcvpp
rntvhcv
week
boost
radhcv
rntvhcv
shown
figur
week
three
group
demonstr
signific
neutral
hcvpp
deriv
genotyp
homolog
immunogen
furthermor
broad
neutral
abil
heterolog
hcvpp
subtyp
detect
singl
vaccin
rntvhcv
hcvpp
crossneutr
abil
potenti
boost
radhcv
week
figur
howev
second
rntv
booster
enhanc
neutral
abil
group
c
radhcv
prime
hcvpp
boost
antigenspecif
tcell
respons
induc
three
immun
regimen
assess
elispot
monkey
bled
week
vaccin
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
stimul
overlap
peptid
span
hcv
target
antigen
cmi
detect
macaqu
prime
hcvpp
week
boost
radhcv
three
monkey
hcvpp
prime
group
demonstr
posit
immun
median
rang
sfumillion
pbmc
maintain
week
median
rang
sfumillion
pbmc
figur
contrast
four
monkey
prime
rntvhcv
show
strong
cmi
respons
median
rang
sfumillion
pbmc
week
cmi
respons
decreas
markedli
week
group
rntvhcv
prime
mark
enhanc
result
radhcv
vaccin
boost
week
median
rang
sfumillion
pbmc
furthermor
cmi
maintain
higher
level
group
rntvhcv
primeradhcv
boost
compar
two
group
week
detect
week
rang
sfumillion
pbmc
figur
week
four
monkey
immun
rad
twice
one
monkey
demonstr
weak
hcvspecif
tcell
respons
rang
sfumillion
pbmc
mainli
peptid
sampl
remain
posit
week
radprim
group
boost
hcvpp
week
although
respons
increas
monkey
group
show
slight
increas
median
rang
sfumillion
pbmc
howev
two
boost
hcvpp
significantli
reinforc
tcell
respons
rntv
boost
week
caus
mark
increas
two
four
macaqu
rad
group
median
rang
sfumillion
pbmc
figur
addit
specif
tcell
respons
also
assess
use
four
separ
peptid
pool
span
four
hcv
vaccin
target
core
rntvhcv
prime
group
exhibit
signific
enhanc
four
peptid
especi
boost
radhcv
week
figur
detail
prime
rntvhcv
induc
two
monkey
group
posit
posit
three
posit
vaccin
effect
singl
administr
boost
radhcv
sampl
group
becam
posit
four
peptid
except
one
monkey
neg
core
compel
advantag
compar
two
regimen
boost
radhcv
also
effect
hcvppprime
group
howev
prime
rad
markedli
enhanc
cmi
group
figur
boost
effect
rntvhcv
similarli
disappoint
group
boost
hcvpp
moreov
use
hcvpp
either
primer
booster
antigen
induc
detect
cmi
also
assess
effect
variou
regimen
cytokin
product
pbmc
freshli
isol
pbmc
stimul
hcv
peptid
pool
supernat
harvest
hour
stimul
cytokin
level
week
assess
commerci
cytokin
kit
use
follow
manufactur
instruct
respect
standard
assay
cytokin
includ
relat
figur
consist
elispot
result
secret
concentr
cytokin
pbmc
group
receiv
rntvrad
vaccin
higher
group
figur
rntvrad
group
also
show
enhanc
cytokin
correl
strongest
hcvspecif
humor
immun
respons
figur
although
rntvrad
group
exhibit
higher
level
two
group
rate
enhanc
peptid
stimul
significantli
lower
hcvppradhcv
group
figur
rhesu
macaqu
vaccin
model
use
tool
evalu
immun
respons
induc
hcv
immunogen
report
herein
first
time
evalu
immunogen
primat
use
novel
replicationdefect
rntvbase
hcv
vaccin
also
perform
first
indepth
analysi
recent
sever
viral
vaccin
candid
shown
great
promis
preclin
clinic
trial
transient
reduc
viral
load
chronic
infect
subject
among
viral
vector
especi
rad
rmvabas
vaccin
candid
heterogen
primeboost
vaccin
may
repres
promis
strategi
develop
hcv
vaccin
distinguish
safeti
record
rttv
coupl
abil
induc
robust
persist
cmi
human
make
liveattenu
vaccin
attract
vector
candid
hcv
vaccin
given
concern
surround
preexist
immun
potenti
risk
rttvbase
vaccin
human
remain
encourag
compar
immunogen
achiev
primat
use
replicationdefect
rntvbase
vaccin
candid
heterolog
primeboost
regimen
rntv
novel
viral
vector
vaccin
base
tiantan
strain
vaccinia
viru
highli
attenu
strain
use
wide
safe
viral
vector
deliv
antigen
vector
effect
amplifi
chicken
embryo
cell
reach
high
titr
effect
reproduc
cell
line
human
rabbit
monkey
make
rntv
vector
easi
produc
safer
human
use
rntv
exhibit
dna
replic
rna
transcript
protein
express
similar
origin
tiantan
strain
express
effici
immunogen
approxim
origin
viru
data
agre
previou
report
rntv
highli
reliabl
primer
antibodi
tcell
respons
studi
show
rntv
vector
excel
immunogen
term
induct
effect
hcvspecif
cellular
humor
immun
respons
rhesu
monkey
neutral
capac
activ
antibodi
weaker
hcvpp
howev
data
also
show
immun
induc
rhesu
macaqu
rntvhcv
vaccin
long
durat
encouragingli
immun
respons
rapidli
stimul
enhanc
radhcv
boost
enhanc
respons
maintain
longer
spectrum
antibodi
may
improv
suggest
prime
rntv
boost
rad
may
ideal
strategi
induc
longlast
protect
immun
hcv
addit
analysi
cytokin
profil
reveal
cytokin
product
hcvspecif
especi
subset
pbmc
macaqu
rntvhcv
primeradhcv
booster
significantli
increas
compar
regimen
figur
multipl
cytokin
detect
cultur
supernat
pbmc
stimul
peptid
week
pbmc
vaccin
rhesu
macaqu
cocultur
peptid
cultur
medium
neg
control
day
cultur
cytokin
supernat
assay
luminex
b
cytokin
quantit
c
cytokin
level
activ
sampl
divid
neg
control
calcul
enhanc
rate
enhanc
rate
among
three
group
compar
twoway
analysi
varianc
cytokin
whose
express
significantli
differ
group
indic
asterisk
p
p
previou
studi
report
adenovir
vector
strategi
induc
sustain
tcell
respons
magnitud
qualiti
associ
protect
immun
hcv
previou
data
indic
vaccin
induc
signific
cmi
mice
howev
nab
detect
agreement
data
also
indic
boost
radhcv
effect
enhanc
cmi
rhesu
macaqu
prime
rntvhcv
hcvpp
data
also
agre
previou
murin
data
demonstr
moder
high
igg
level
induc
radhcv
prime
howev
radhcv
prime
fail
induc
robust
nab
respons
hcv
macaqu
furthermor
radhcv
boost
also
fail
significantli
broaden
enhanc
nab
respons
hcv
macaqu
prime
hcvpp
addit
recent
studi
shown
hcv
pseudoparticl
base
retrovir
vector
effect
trigger
product
broadspectrum
nab
mice
rhesu
macaqu
consid
critic
factor
prevent
infect
highli
variabl
virus
hcv
hiv
develop
doubleeffect
vaccin
induc
cellular
humor
immun
hcv
develop
novel
hcvpp
envelop
protein
hcv
within
pack
gene
ssrna
form
base
integrationdefici
lentivir
vector
platform
previou
work
mice
initi
confirm
novel
hcvpp
exhibit
specif
cellularimmunityenhanc
abil
induc
product
crossnab
therefor
new
hcvpp
vaccin
may
also
exhibit
doubleactiv
abil
rhesu
macaqu
use
rad
prime
hcvpp
boost
immun
strategi
previou
studi
hcvpp
vaccin
also
elicit
strong
humor
immun
respons
hcv
antigen
macaqu
broadspectrum
neutral
activ
also
induc
prime
hcvpp
boost
radhcv
although
obviou
enhanc
antibodi
respons
hcv
radhcv
boost
may
play
import
role
induct
crossneutr
respons
vaccin
howev
prime
hcvpp
fail
induc
robust
cmi
hcv
macaqu
attempt
induc
immun
rntvhcv
vaccin
follow
radhcvhcvpp
howev
total
igg
nab
hcv
show
downward
trend
although
cmi
induc
possibl
caus
phenomenon
regul
cytokin
hcvpp
tend
activ
cytokin
product
b
cell
amplif
rntv
may
result
dual
induct
intervent
rntv
high
level
cytokin
activ
neg
feedback
regul
dendrit
cell
dc
natur
killer
cell
unfortun
unabl
assay
cytokin
cell
sort
would
allow
differenti
cytokin
express
profil
cell
cell
dc
natur
killer
summari
knowledg
first
evalu
immunogen
primat
use
novel
replicationdefect
rntvbase
hcv
vaccin
data
suggest
favor
regim
clinic
trial
hcv
vaccin
would
rntvhcv
prime
follow
radhcv
boost
would
induc
optim
polyfunct
cmi
broad
nab
simultan
larger
anim
speci
data
might
also
import
implic
vaccin
develop
persist
infect
tb
cancer
date
gene
encod
protein
nonstructur
compon
hcv
subtyp
hebei
strain
construct
previous
gene
convent
subclon
poxviru
shuttl
vector
deriv
laboratori
place
insert
gene
control
vaccinia
viru
promot
provid
flank
recombin
tk
locu
ntv
figur
ntvjtk
replicationdefect
tiantan
strain
vaccinia
viru
ntv
ck
region
delet
supplementari
figur
use
origin
viru
recombin
virus
isol
follow
transfect
plasmid
infect
primari
chick
embryo
fibroblast
day
gestat
transient
domin
select
use
lacz
immun
virus
amplifi
chick
embryo
fibroblast
purifi
sucros
cushion
titr
plaqu
form
unit
pfu
determin
twice
duplic
plaqu
assay
accord
standard
method
synthet
core
gene
use
construct
adenoviru
vector
gene
prepar
describ
previous
construct
use
strategi
briefli
hcv
target
gene
clone
region
replicationdefect
adenovir
serotyp
vector
control
hcmv
immediateearli
promoterenhanc
stoppolyadenyl
signal
radhcv
vaccin
rescu
amplifi
cell
dose
base
viral
particl
vp
determin
maizel
spectroscop
method
aa
insert
pvrc
envelop
plasmid
transduc
plasmid
pc
integrationdefici
packag
plasmid
contain
point
mutat
integras
domain
human
immunodefici
viru
hiv
construct
laboratori
three
plasmid
cotransfect
human
embryon
kidney
hek
cell
use
fugen
hd
reagent
roch
basel
switzerland
hcvpp
figur
harvest
hour
transfect
viru
titr
present
hiv
antigen
concentr
determin
use
vironostika
antigen
microelisa
system
shanghai
china
rhesu
macaqu
hous
laboratori
anim
centr
academi
militari
medic
scienc
pla
amm
rhesu
macaqu
consist
seven
femal
seven
male
year
age
weigh
kg
monkey
assign
group
manner
ensur
homogen
age
bodi
weight
distribut
case
total
vaccin
dose
suspend
ml
nacl
macaqu
anaesthet
ketamin
vaccin
deliv
intramuscularli
aliquot
deltoid
muscl
via
tuberculin
syring
bectondickinson
new
york
ny
anim
care
treatment
accord
standard
approv
institut
anim
care
use
committe
nation
institut
viral
diseas
control
prevent
nivdc
china
conform
nation
intern
law
polici
offic
laboratori
anim
welfar
approv
nivdc
anim
welfar
assur
anim
involv
studi
met
follow
criteria
good
health
free
known
infecti
immunolog
diseas
previou
contact
pathogen
relat
hcv
anim
sacrif
end
studi
solubl
hcv
protein
prepar
describ
previous
purifi
coat
onto
plate
corn
ny
elisa
core
antibodi
titr
determin
use
commerci
hcv
elisa
detect
kit
waitai
biotech
beij
china
serum
sampl
dilut
serial
determin
antigenspecif
endpoint
titr
defin
reciproc
last
dilut
give
od
twice
mock
serum
monkey
vaccin
nab
assay
infecti
hcvpp
variou
gene
produc
evalu
induct
nab
serial
dilut
sera
purif
use
protein
g
column
incub
hcvpp
mixtur
use
infect
cell
hour
luciferas
activ
infect
cell
measur
use
brightglo
luciferas
assay
system
promega
madison
wi
centrox
luminomet
berthold
bad
wildbad
germani
data
express
rel
luminesc
unit
rlu
percentag
neutral
calcul
compar
luciferas
activ
cell
infect
hcvpp
presenc
serum
immun
anim
cell
infect
hcvpp
presenc
preimmun
serum
anim
elispot
macaqu
pbmc
isol
edtatr
blood
ficollpaqu
plu
ge
healthcar
piscataway
nj
densiti
centrifug
resuspend
complet
media
rpmi
fc
mmoll
glutamin
mmoll
sodium
bicarbon
penicillinstreptomycin
elispot
assay
carri
accord
manufactur
instruct
mabtech
stockholm
sweden
briefli
pbmc
per
well
stimul
appropri
peptid
final
concentr
pvdf
membranebottom
plate
precoat
antimonkey
captur
antibodi
test
well
run
use
two
replic
set
neg
control
well
compris
media
includ
plate
pool
peptid
overlap
amino
acid
span
hcv
target
protein
core
includ
vaccin
regimen
stimul
hour
cell
detect
stain
membran
detect
antibodi
follow
streptavidinhorseradish
peroxidas
develop
tmb
substrat
solut
result
present
spotform
cell
per
pbmc
respons
compris
spotform
cell
per
cell
consid
neg
evalu
statist
determin
posit
valu
report
mean
test
well
minu
mean
negativecontrol
well
luminex
assay
pbmc
stimul
peptid
pool
use
elispot
cellfre
cultur
supernat
harvest
hour
stimul
divid
aliquot
detect
simultan
use
procarta
immunoassay
kit
affymetrix
santa
clara
ca
aliquot
combin
coat
bead
detect
follow
direct
manufactur
incub
wash
perform
filter
membran
microtitr
plate
millipor
billerica
help
multiscreen
vacuum
manifold
plate
millipor
final
wash
bead
resuspend
read
buffer
concentr
read
use
luminex
instrument
bioplex
biorad
hercul
ca
statist
analysi
statist
analys
perform
graph
plot
use
graphpad
prism
version
graphpad
softwar
la
jolla
ca
data
log
transform
oneway
twoway
analysi
varianc
perform
figur
legend
denot
test
perform
experi
elisa
endpoint
titr
normal
log
transform
analysi
appropri
mean
fold
chang
elisa
titr
ci
report
comparison
mean
immun
respons
among
group
macaqu
perform
lsd
oneway
analysi
varianc
bonferroni
twoway
analysi
varianc
test
correl
analyz
use
spearman
rank
test
signific
differ
among
group
evalu
p
valu
state
figur
legend
figur
character
vaccinia
viru
tiantan
strain
replicationcompet
vvt
replicationdefect
ntv
